S-1/A: Catheter Precision Eyes $3.45 Million in Unit Offering to Bolster Operations

Catheter Precision is undertaking a firm commitment public offering of common stock and pre-funded warrant units to raise capital for clinical trials, working capital, and general corporate purposes.

Summary

• Catheter Precision, Inc. is planning a public offering to sell up to 1,357,466 common stock units, each including one share of common stock and warrants to purchase additional shares.
• The company is also offering pre-funded warrant units as an alternative for purchasers who would exceed beneficial ownership limits with the common stock units.
• The assumed public offering price is $2.21 per common stock unit, based on the August 19, 2024, closing price, and $2.2099 per pre-funded warrant unit.
• The Series H warrants will expire in six months, Series I in eighteen months, and Series J in five years from the offering's closing date.
• The offering includes underwriter warrants to purchase up to 81,447 shares of common stock.
• David Jenkins, CEO and Chairman of the Board, has expressed interest in purchasing up to $500,000 of common stock units in the offering.
• The company intends to use the net proceeds for clinical trials, working capital, and general corporate purposes, including repaying approximately $21,000 in interest to David Jenkins.
• The company has granted the underwriters an option to purchase up to 203,619 additional shares and/or warrants to cover over-allotments.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is raising capital and has growth plans, it faces significant risks, including dilution, lack of liquidity for new securities, and a history of losses. The CEO's participation is a positive sign, but the overall outlook is uncertain.

Positives

• The offering aims to raise capital for clinical trials, which could lead to product advancements.
• The funds will also support working capital, providing financial flexibility.
• CEO's participation signals confidence in the company's prospects.

Negatives

• The offering will cause immediate and substantial dilution to new investors.
• The company has broad discretion in using the proceeds, which may not yield favorable returns.
• There is no established public trading market for the units or warrants, limiting liquidity.
• The company has a history of losses and may never achieve profitability.

Risks

• The company may not use the proceeds effectively.
• Investors will experience immediate and substantial dilution.
• The issuance of additional equity securities may negatively impact the trading price.
• There is no public market for the common warrants or pre-funded warrants.
• Significant holders may not be permitted to exercise warrants due to ownership limitations.
• The company will be required to raise additional funds to finance its operations and continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company aims to establish VIVO and LockeT as integral tools used by cardiac electrophysiologists during and following ablation treatment of ventricular arrhythmias, by reducing procedure time and patient complications and increasing procedural efficiencies and success.

Industry Context

The electrophysiology (EP) market is estimated to reach $15.1 billion by 2028, with a CAGR of 13.0%. The catheter ablation market was larger than $3.5 billion in 2022 and is estimated to grow to $14.5 billion by 2032 (13.5% CAGR).

Comparison to Industry Standards

• The EP market includes large medical device companies such as Medtronic, Plc., Abbott Laboratories, Biosense-Webster (J&J) and Boston Scientific Corp.
• LockeTs direct competitors include Abbotts Perclose device, Haemonetics VASCADE device and Inari Medicals FlowStasis device.

Related Party Transactions

• David Jenkins, CEO and Chairman of the Board, has expressed interest in purchasing up to $500,000 of common stock units in the offering.
• The company intends to use the net proceeds for clinical trials, working capital, and general corporate purposes, including repaying approximately $21,000 in interest to David Jenkins.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may benefit from increased investment in the company's growth.
• Customers may benefit from product advancements resulting from clinical trials.
• Creditors may benefit from the company's improved financial stability.

Next Steps

• The company will continue to build out its sales network for both VIVO and LockeT.
• The company will continue to use direct clinical specialists to provide training and ongoing clinical support.
• The company intends to market its products in the U.S. and certain international markets using a combination of a direct sales force and independent distributors.
• The company intends to develop a generation 3 of VIVO.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Catheter Precision, units, Series H, Series I, Series J, VTAK